|
|
 |
|
Viewing report
|
|
|
|
Epidemiology: Psoriasis
Datamonitor, March 2011, Pages: 26
Introduction
By 2019, the seven major markets will count 15 million psoriasis cases; around half of which will be living in the US. With the exception of Japan, the psoriasis population is expected to increase in all markets.
Features and benefits
- Gain insight to market potential, including a robust 10-year epidemiology forecast of prevalent psoriasis cases.
- Understand the key epidemiologic risk factors associated with psoriasis disease.
Highlights
- Of the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK), psoriasis prevalence is expected to increase the most in the US, less in Europe, and decline slightly in Japan over the next decade
- Psoriasis is a life-long disease with low mortality and high morbidity, which can severely affect a patient’s quality of life.
Your key questions answered
- What are the most robust epidemiologic studies for psoriasis prevalence data?
- How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
- How do changes in population structure and risk factors affect the trend in prevalent psoriasis cases?
|
|
|
|
